In cancer patients, the tumor microenvironment triggers a persistent systemic inflammatory response characterized by elevated cytokines such as IL-6, TNF-α, and IL-1β, which can impair renal vascular tone and lead to renal hypoperfusion and structural kidney damage over time. This evidence concerns the gene IL6 and cancer.